Can I stop taking eculizumab suddenly?

See full prescribing information for. SOLIRIS. SOLIRIS® (eculizumab) injection, for intravenous use. Initial U.S. Approval: 2007. WARNING: SERIOUS MENINGOCOCCAL ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ... Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ...